Selbyville, Delaware, Jan. 23, 2025 (GLOBE NEWSWIRE) --
Neurological biomarkers market size was valued at USD 9.5 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 10.9% between 2025 and 2034. The rising prevalence of neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease, is a key factor driving market growth. This increase in neurological conditions is primarily attributed to the aging population, with Alzheimer’s disease becoming increasingly common among older adults.
Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/12334
The surge in these disorders has fueled demand for personalized medicine, as tailored treatments can lead to better outcomes for patients. Advancements in genomics, proteomics, and imaging technologies are also playing a pivotal role in the early detection and diagnosis of neurological diseases. Biomarkers that identify specific proteins, genes, or metabolites in the brain or blood have significantly enhanced diagnostic accuracy, enabling healthcare professionals to provide timely and effective treatment.
Neurological biomarkers serve as critical indicators for assessing the presence and progression of various neurological diseases. These biomarkers can be molecules, genes, or other substances linked to conditions such as Alzheimer’s, Parkinson’s, multiple sclerosis, and autism spectrum disorders.
The neurological biomarkers market is segmented by product type into proteomic, genomic, metabolomic, imaging, and other biomarkers. Among these, the proteomic biomarker segment led the market in 2024, accounting for USD 3.1 billion, driven by advancements in technologies like liquid chromatography–mass spectrometry (LC-MS/MS) and multiplex assays.
These innovations have improved the sensitivity and reliability of proteomic tests, allowing for earlier detection and better management of neurological conditions. Additionally, the growing focus on precision medicine is expected to boost demand for proteomic biomarkers in both clinical settings and drug development.
By disease type, Alzheimer’s disease held the largest neurological biomarkers market share of 45.5% in 2024, reflecting the urgent need for early diagnostic solutions. Blood-based biomarkers have emerged as a less invasive and more cost-effective alternative to traditional cerebrospinal fluid tests, further driving market growth.
The hospitals and clinics segment dominated the market by end use in 2024 and is projected to reach USD 11 billion by 2034. These facilities are increasingly adopting non-invasive biomarker diagnostics, improving patient outcomes through personalized care. Government support, funding for research, and collaborations with private organizations are also accelerating the integration of biomarkers into routine clinical practice.
In North America, the U.S. held a significant share of the neurological biomarkers market in 2024, valued at USD 3.7 billion. The region benefits from technological advancements, increased focus on precision medicine, and a rising demand for personalized therapies tailored to individual genetic and disease profiles.
Request for Report Customization @ https://www.gminsights.com/roc/12334
Major players in neurological biomarkers market include Abbott Laboratories, ACOBIOM, Alseres Pharmaceuticals, Banyan Biomarkers, Bio-Rad Laboratories, DiaGenic ASA, Johnson & Johnson Services, Merck KGaA, QIAGEN, Quanterix, Rules-Based Medicine, and Thermo Fisher Scientific among others.
Partial Table of Contents (ToC) of the report:
Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of neurological disorders
3.2.1.2 Advancement in biomarker research
3.2.1.3 Adoption of personalized medicine
3.2.1.4 Rising awareness among patients and healthcare providers of neurological disorders
3.2.2 Industry pitfalls and challenges
3.2.2.1 High cost of biomarker testing
3.2.2.2 Lack of standardization
3.3 Growth potential analysis
3.4 Future market trends
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Browse more diagnostic devices industry reports @ https://www.gminsights.com/industry-reports/diagnostic-devices/82
About Global Market Insights
Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.
